TuHURA Biosciences (HURA)

• Market cap: $107M
• 1 day: -3.06%
• 5 days: 24.18%
• 1 month: 42.86%
• 3 months: 97.22%
• 6 months: -20.5%
• Year to date: 153.5%
• 1 year: -4.04%
• 5 years: -99.95%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Employees: 19